Changes of Clinical Characteristics, Distribution of Red Flags and Prognosis in Contemporary Patients with Wild-type Transthyretin Amyloidosis Cardiomyopathy

Overview

Journal Ann Med

Publisher Informa Healthcare

Specialty General Medicine

Date 2024 Sep 9

PMID 39247984

Authors

Larsen Sanne Bojet

Ladefoged Bertil

Pedersen Anders Lehmann Dahl

Skov Jens Kaestel

Clemmensen Tor Skibsted

Poulsen Steen Hvitfeldt

Affiliations

Soon will be listed here.

Abstract

Aim: Increased diagnostic awareness and specific disease treatments have changed the landscape of transthyretin cardiac amyloidosis (ATTR). Patients with wild-type ATTR (ATTRwt) are increasingly being diagnosed, potentially changing the clinical profile and prognosis compared with existing retrospective data. We aimed to study the clinical characteristics, distribution of red flags and prognosis of contemporary ATTRwt patients.

Methods: From January 1 2017, to December 31 2022, 213 consecutive patients were diagnosed with ATTRwt and prospectively followed up. Data on clinical characteristics, biomarkers, echocardiography findings, hospitalization due to worsening heart failure (WHF) and all-cause mortality were collected.

Results: A 37% increase in newly diagnosed patients from 2017-2019 ( = 90) vs. 2020-2022 ( = 123) was observed. The majority of patients presented with NAC disease stage I in the latter period (49% in 2017-2019 vs. 58% in 2020-2022, = .16). Red flags were primarily cardiac-related, including elevated NT-proBNP, impaired left ventricular longitudinal systolic strain with an apical sparing pattern, heart failure with increased left ventricular wall thickness and elevated troponins. NAC disease stage I as well as low NT-proBNP levels (<1000 ng/L) were significantly associated with better survival (both < .001). When compared with NAC disease stage II + III combined, patients with NAC disease stage I had a significantly lower risk of WHF hospitalization or death (log rank test: = .0001). Independent predictors of the combined endpoint WHF hospitalization or death were NT-proBNP (HR 1.03 [95% CI 1.00-1.07], < .049) and prior implantation of permanent pacemaker (HR 2.01 [1.30-3.11], = .002).

Conclusion: Increased diagnostic awareness resulted in a 37% increase in newly diagnosed patients in 2020-2022 vs. 2017-2019. As expected all-cause mortality but also the morbidity in terms of risk of hospitalization with WHF were significantly lower in patients with NAC disease stage I, as well as in those with low NT-proBNP levels <1000 ng/L. These findings underline the importance of continuous attention to diagnostic awareness, as early diagnosis is critical for initiating both general and specific ATTR treatment, thus improving prognosis.

References

Porcari A, Rossi M, Cappelli F, Canepa M, Musumeci B, Cipriani A . Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis. Eur J Heart Fail. 2022; 24(7):1227-1236. DOI: 10.1002/ejhf.2533. View

Milandri A, Farioli A, Gagliardi C, Longhi S, Salvi F, Curti S . Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies. Eur J Heart Fail. 2020; 22(3):507-515. DOI: 10.1002/ejhf.1742. View

Grogan M, Scott C, Kyle R, Zeldenrust S, Gertz M, Lin G . Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol. 2016; 68(10):1014-20. DOI: 10.1016/j.jacc.2016.06.033. View

Law S, Petrie A, Chacko L, Cohen O, Ravichandran S, Gilbertson J . Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage. ESC Heart Fail. 2020; 7(6):3942-3949. PMC: 7755026. DOI: 10.1002/ehf2.12989. View

Gonzalez-Lopez E, Gagliardi C, Dominguez F, Quarta C, de Haro-Del Moral F, Milandri A . Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J. 2017; 38(24):1895-1904. DOI: 10.1093/eurheartj/ehx043. View

Porcari A, Cappelli F, Nitsche C, Tomasoni D, Sinigiani G, Longhi S . SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol. 2024; 83(24):2411-2422. DOI: 10.1016/j.jacc.2024.03.429. View

Cappelli F, Perfetto F, Martone R, Di Mario C . Cardiac Amyloidosis in Patients Undergoing TAVR: Why We Need to Think About It. Cardiovasc Revasc Med. 2020; 22:109-114. DOI: 10.1016/j.carrev.2020.06.005. View

Solomon S, Adams D, Kristen A, Grogan M, Gonzalez-Duarte A, Maurer M . Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Circulation. 2018; 139(4):431-443. DOI: 10.1161/CIRCULATIONAHA.118.035831. View

Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A . Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021; 42(16):1554-1568. PMC: 8060056. DOI: 10.1093/eurheartj/ehab072. View

10.

Lang R, Badano L, Mor-Avi V, Afilalo J, Armstrong A, Ernande L . Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015; 28(1):1-39.e14. DOI: 10.1016/j.echo.2014.10.003. View

11.

McDonagh T, Metra M, Adamo M, Gardner R, Baumbach A, Bohm M . 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023; 44(37):3627-3639. DOI: 10.1093/eurheartj/ehad195. View

12.

Maurer M, Schwartz J, Gundapaneni B, Elliott P, Merlini G, Waddington-Cruz M . Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018; 379(11):1007-1016. DOI: 10.1056/NEJMoa1805689. View

13.

Lauppe R, Hansen J, Fornwall A, Johansson K, Rozenbaum M, Strand A . Healthcare resource use of patients with transthyretin amyloid cardiomyopathy. ESC Heart Fail. 2022; 9(3):1636-1642. PMC: 9065857. DOI: 10.1002/ehf2.13913. View

14.

Ruberg F, Maurer M . Cardiac Amyloidosis Due to Transthyretin Protein: A Review. JAMA. 2024; 331(9):778-791. PMC: 11167454. DOI: 10.1001/jama.2024.0442. View

15.

Gillmore J, Maurer M, Falk R, Merlini G, Damy T, Dispenzieri A . Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016; 133(24):2404-12. DOI: 10.1161/CIRCULATIONAHA.116.021612. View

16.

Lindmark K, Pilebro B, Sundstrom T, Lindqvist P . Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic. ESC Heart Fail. 2020; 8(1):745-749. PMC: 7835553. DOI: 10.1002/ehf2.13110. View

17.

Pilgaard T, Pedersen M, Hvitfeldt Poulsen S . Diagnostic and lifetime hospital costs of patients suffering from wild-type transthyretin amyloid cardiomyopathy in Denmark. J Med Econ. 2020; 23(10):1084-1091. DOI: 10.1080/13696998.2020.1789866. View

18.

Porcari A, Fontana M, Gillmore J . Transthyretin cardiac amyloidosis. Cardiovasc Res. 2022; 118(18):3517-3535. PMC: 9897687. DOI: 10.1093/cvr/cvac119. View

19.

Ladefoged B, Dybro A, Povlsen J, Vase H, Clemmensen T, Hvitfeldt Poulsen S . Diagnostic delay in wild type transthyretin cardiac amyloidosis - A clinical challenge. Int J Cardiol. 2020; 304:138-143. DOI: 10.1016/j.ijcard.2019.12.063. View

20.

Bay K, Gustafsson F, Maiborg M, Bagger-Bahnsen A, Strand A, Pilgaard T . Suspicion, screening, and diagnosis of wild-type transthyretin amyloid cardiomyopathy: a systematic literature review. ESC Heart Fail. 2022; 9(3):1524-1541. PMC: 9065854. DOI: 10.1002/ehf2.13884. View